Evidence map›Paper›PMID 26646841›Full record

ArticleJournal of neuroinflammation2015

Dental follicle mesenchymal stem cell administration ameliorates muscle weakness in MuSK-immunized mice.

Canan Ulusoy, Noushin Zibandeh, Selin Yıldırım, Nikolaos Trakas, Paraskevi Zisimopoulou, Melike Küçükerden, Hatice Tașlı, Socrates Tzartos, Kamil Göker, Erdem Tüzün and 1 more

Abstract read
In one paragraph

Article in Journal of neuroinflammation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. [Biological characteristics and translational research of dental stem cells].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2025
    Review
  4. The Therapeutic Scope of Orofacial Mesenchymal Stem Cells.Bioengineering (Basel, Switzerland) · 2025
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Canan UlusoyDepartment of Neuroscience, Institute for Experimental Medical Research (DETAE), Istanbul University, Istanbul, Turkey.
Noushin ZibandehDivision of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Selin YıldırımDivision of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.
Nikolaos TrakasDepartment of Neurobiology, Hellenic Pasteur Institute, Athens, Greece.
Paraskevi ZisimopoulouDepartment of Neurobiology, Hellenic Pasteur Institute, Athens, Greece.
Melike KüçükerdenDepartment of Neuroscience, Institute for Experimental Medical Research (DETAE), Istanbul University, Istanbul, Turkey.
Hatice TașlıDepartment of Neuroscience, Institute for Experimental Medical Research (DETAE), Istanbul University, Istanbul, Turkey.
Socrates TzartosDepartment of Neurobiology, Hellenic Pasteur Institute, Athens, Greece.
Kamil GökerDepartment of Oral and Maxillofacial Surgery, Marmara University Faculty of Dentistry, Istanbul, Turkey.
Erdem TüzünDepartment of Neuroscience, Institute for Experimental Medical Research (DETAE), Istanbul University, Istanbul, Turkey. drerdem@yahoo.com.
Tunç AkkoçDivision of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction (NMJ), mostly associated with acetylcholine receptor (AChR) antibodies. Around 5-10 % of MG patients show antibodies to muscle-specific tyrosine kinase (MuSK). Mesenchymal stem cell (MSC) administration has been shown to ameliorate muscle weakness in the experimental autoimmune myasthenia gravis (EAMG) model induced by AChR immunization.

methodsTo investigate the efficacy of stem cell treatment in MuSK-related EAMG, clinical and immunological features of MuSK-immunized mice with or without dental follicle MSC (DFMSC) treatment were compared.

resultsMuSK-immunized mice intravenously treated with DFMSC after second and third immunizations showed significantly lower EAMG incidence and severity and reduced serum anti-MuSK antibody, NMJ IgG, and C3 deposit levels and CD11b+ lymph node cell ratios. Moreover, lymph node cells of DFMSC-administered mice showed reduced proliferation and IL-6 and IL-12 production responses to MuSK stimulation. By contrast, proportions of B and T cell populations and production of a wide variety of cytokines were not affected from DFMSC treatment.

conclusionsOur results suggest that DFMSC treatment shows its beneficial effects mostly through suppression of innate immune system, whereas other immune functions appear to be preserved. Stem cell treatment might thus constitute a specific and effective treatment method in MuSK-associated MG.

Indexed as

AnimalsCells, CulturedDental SacFemaleHumansImmunizationMesenchymal Stem CellsMesenchymal Stem Cell TransplantationMiceMice, Inbred C57BLMuscle WeaknessReceptor Protein-Tyrosine KinasesReceptors, CholinergicMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, Cholinergic

Identifiers

PMID26646841
PMCPMC4673854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.